D. Magrez

发表

Issues in performing a network meta-analysis

S. Senn, F. Gavini, D. Magrez, 2013, Statistical methods in medical research.

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.

D. Magrez, K. Kowdley, V. Luketic, 2021, Journal of hepatology.

LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

D. Magrez, K. Kowdley, V. Luketic, 2019, Journal of Hepatology.

An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis

Bachirou O Taddé, D. Magrez, J. Schwimmer, 2023, Journal of pediatric gastroenterology and nutrition.